Britain adopts more stringent rules for phase I trials of high-risk compounds.
Sinha
Gunjan
G
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards*; D006801:Humans; D012307:Risk Factors; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents